{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jiang T"],"funding":["Key Basic Research Project of Shenzhen Science and Technology Research and Development Fund","National Center for Technology Innovation in Biopharmaceuticals","Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine Talent Innovation Team","Guangxi Natural Science Foundation","Key Area Research and Development Program of GuangDong Province","National Natural Science Foundation of China","Wellcome Trust","Shenzhen Science and Technology Program"],"pagination":["e17205"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12499455"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(37)"],"pubmed_abstract":["CD47 inhibitors have emerged as promising candidates in cancer immunotherapy by activating macrophage phagocytosis through CD47/SIRPα signal blockade and enhancing dendritic cell antigen presentation. However, their clinical efficacy remains limited and is accompanied by severe side effects, including anemia and hemagglutination. To address these limitations, a localized delivery strategy is developed using lipid nanoparticles to encapsulate mRNA encoding a secreted CD47 inhibitor. This mRNA-derived CD47 inhibitor effectively activated macrophages against cancer cells in vitro. To improve its modest tumor-suppressive effects in vivo, a combination therapy is formulated by co-delivering mRNAs encoding the CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21), achieving synerg"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity."],"pmcid":["PMC12499455"],"funding_grant_id":["GZCX20231202","KQTD20200909113758004","2022B1111050001","NCTIB2022HS01005","82460960","82273841","22023JJA140431","202414","JCYJ20220818100402004"],"pubmed_authors":["Li H","Cai T","Jing S","Zhong X","Jiang T","Sun X","Wang J","Wei M","Wang PG","Liang J","Hu H","Ji Y","Jin J","Xiao B","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity.","description":"CD47 inhibitors have emerged as promising candidates in cancer immunotherapy by activating macrophage phagocytosis through CD47/SIRPα signal blockade and enhancing dendritic cell antigen presentation. However, their clinical efficacy remains limited and is accompanied by severe side effects, including anemia and hemagglutination. To address these limitations, a localized delivery strategy is developed using lipid nanoparticles to encapsulate mRNA encoding a secreted CD47 inhibitor. This mRNA-derived CD47 inhibitor effectively activated macrophages against cancer cells in vitro. To improve its modest tumor-suppressive effects in vivo, a combination therapy is formulated by co-delivering mRNAs encoding the CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21), achieving synerg","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T04:43:35.536Z","creation":"2026-05-05T03:12:22.026Z"},"accession":"S-EPMC12499455","cross_references":{"pubmed":["40652522"],"doi":["10.1002/advs.202417205"]}}